Revised SPCs: Taltz (ixekizumab) 80 mg solution for injection – all products
Two new indications added; active axial spondyloarthritis in patients who have responded inadequately to conventional therapy, and active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation.
Source:
electronic Medicines compendium